Cytotoxics and High Potency Manufacturing
- All
- APIs
- Aseptic Processing
- cGMP Manufacture
- Cleaning Validation
- Clinical Trial Materials
- Cytotoxics and High Potency Manufacturing
- Excipients
- Extractables and Leachables
- Facilities
- Fill/Finish
- Lyophilization
- Parenterals
- Process Development
- Process Validation
- Risk Management
- Scale-up/Technology Transfer
- Solid Dosage/Creams/Ointments
-
Bio News | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Sterling Pharma Solutions Acquires ADC Biotechnology
Will establish a center of excellence for bioconjugation and ADC development and manufacturing services.Tim Wright, Editor, Contract Pharma 04.07.21
-
Cytotoxics and High Potency Manufacturing | Facilities | Solid Dosage/Creams/Ointments
Outsourcing Solid Dosage Manufacturing
A Q&A with Dan Dobry, head of drug product commercial development at Lonza Pharma & Biotech.Online Exclusives Tim Wright, Editor, Contract Pharma 03.12.21
-
APIs | Cytotoxics and High Potency Manufacturing
Challenges & Opportunities Facing Small & Emerging Biopharma Companies
A Q&A with Christian Dowdeswell, vice president and head of commercial development for small molecules at Lonza.Tim Wright, Editor, Contract Pharma 03.01.21
-
Breaking News | Cytotoxics and High Potency Manufacturing | Drug Delivery | Facilities | Industry News
Inhalation CDMO Vectura Expands HPAPI Capabilities
New facility will increase containment operations at Chippenham, UK site.Contract Pharma Staff 12.14.20
-
APIs | Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Piramal Invests $32M to Expand Michigan Facility
Includes additional capacity in Potent and Non-Potent API development and manufacturing.Contract Pharma Staff 12.08.20
-
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Catalent Invests $10M in Isolator Capabilities to Expand Micronization
Will allow flexible jet milling ops to be carried out at sites in Malvern, PA and Dartford, U.K. under high containment.Contract Pharma Staff 12.04.20
-
cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Lonza Expands HPAPI Capabilities
Invests more than $15 million to expand and upgrade the Tampa, FL site.Contract Pharma Staff 11.18.20
-
Breaking News | Collaborations & Alliances | Cytotoxics and High Potency Manufacturing | Industry News
Lonza Opens Facility for ADC Payload Manufacturing
Expansion is based on agreement with a major biopharma partner that ensures ADC payload supply continuity and flexibility.Contract Pharma Staff 11.05.20
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
CordenPharma Colorado Completes Highly Potent API Lab Expansion
Capable of handling highly potent compounds with an OEL as low as 1ng/m3.Contract Pharma Staff 10.19.20
-
Aseptic Processing | Breaking News | Collaborations & Alliances | Cytotoxics and High Potency Manufacturing | Industry News
ILC Dover Acquires Solo Containment
UK-based provider of products used in pharmaceutical and biopharmaceutical manufacturing.Contract Pharma Staff 09.14.20
-
Biologics, Proteins, Vaccines | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
MilliporeSigma Expands HPAPI and ADC Mfg. Capabilities
$65 million investment to expand facility near Madison, WI will allow large-scale manufacturing of increasingly potent compounds.Contract Pharma Staff 09.09.20
-
Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
Seqens Opens New HPAPI Unit
Will produce highly active ingredients at its Villeneuve-La-Garenne site.Contract Pharma Staff 09.03.20
-
Breaking News | cGMP Manufacture | Cytotoxics and High Potency Manufacturing | Industry News
Catalent to Expand Argentinian Site in Buenos Aires
Adding 11,000 sq.-ft. of production space segregated and designed to handle cytotoxic and highly active products for prescription softgel manufacturing.Contract Pharma Staff 08.04.20
-
APIs | Cytotoxics and High Potency Manufacturing
The CDMO Landscape: Controlled Substance APIs
Meeting the growing demand for the development and manufacture of controlled substance APIs.Mike Gibson, R&D Director, Sterling Pharma Solutions 06.04.20
-
Cytotoxics and High Potency Manufacturing
Highly Potent and Highly Specialized
CDMO model meets the HPAPI market demand.Youchu Wang, VP Process R&D, WuXi STA 06.04.20
-
Cytotoxics and High Potency Manufacturing
HPAPI Drug Manufacturing Trends
Managing accelerated timelines in manufacturing high-potency drugs.Maurits Janssen, Head of Commercial Development, Lonza Pharma & Biotech 05.05.20
-
Cytotoxics and High Potency Manufacturing | Fill/Finish | Information Technology
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Industry News
Piramal to Expand Aurora Facility
To add 10,500 sq.-ft. state-of-the-art wing dedicated to manufacturing Active Pharmaceutical Ingredients01.28.20
-
cGMP Manufacture | Cytotoxics and High Potency Manufacturing
HPAPI Market Trends: PCI Expands Capabilities
Michael Ellingson of PCI discusses market demand for specialty drug product capabilities and the Rockford, IL expansionOnline Exclusives Kristin Brooks, Cotract Pharma 01.10.20
-
APIs | Breaking News | Cytotoxics and High Potency Manufacturing | Facilities | Industry News
